ProQR Therapeutics NV (PRQR)
1.625
-0.02
(-1.52%)
USD |
NASDAQ |
Oct 07, 16:00
1.625
0.00 (0.00%)
After-Hours: 19:48
ProQR Therapeutics Net Income (Quarterly) : -10.15M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.15M |
| March 31, 2026 | -15.66M |
| December 31, 2025 | -10.38M |
| September 30, 2025 | -12.86M |
| June 30, 2025 | -13.80M |
| March 31, 2025 | -10.61M |
| December 31, 2024 | -9.926M |
| September 30, 2024 | -8.907M |
| June 30, 2024 | -2.898M |
| March 31, 2024 | -8.312M |
| December 31, 2023 | -5.896M |
| September 30, 2023 | -5.896M |
| June 30, 2023 | -8.682M |
| March 31, 2023 | -9.501M |
| December 31, 2022 | -13.56M |
| September 30, 2022 | -23.47M |
| June 30, 2022 | -15.61M |
| March 31, 2022 | -16.21M |
| December 31, 2021 | -20.85M |
| September 30, 2021 | -17.76M |
| June 30, 2021 | -18.99M |
| March 31, 2021 | -15.20M |
| December 31, 2020 | -15.77M |
| September 30, 2020 | -15.42M |
| June 30, 2020 | -4.536M |
| Date | Value |
|---|---|
| March 31, 2020 | -17.71M |
| December 31, 2019 | -20.57M |
| September 30, 2019 | -13.55M |
| June 30, 2019 | -13.18M |
| March 31, 2019 | -16.17M |
| December 31, 2018 | -14.81M |
| September 30, 2018 | -6.970M |
| June 30, 2018 | -8.812M |
| March 31, 2018 | -13.17M |
| December 31, 2017 | -13.32M |
| September 30, 2017 | -12.36M |
| June 30, 2017 | -12.52M |
| March 31, 2017 | -11.17M |
| December 31, 2016 | -9.504M |
| September 30, 2016 | -11.30M |
| June 30, 2016 | -11.25M |
| March 31, 2016 | -11.24M |
| December 31, 2015 | -6.705M |
| September 30, 2015 | -7.021M |
| June 30, 2015 | -9.540M |
| March 31, 2015 | 0.2642M |
| December 31, 2014 | -2.544M |
| September 30, 2014 | -4.471M |
| June 30, 2014 | -6.576M |
| March 31, 2014 | -2.629M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Pharming Group NV | 1.598M |
| NewAmsterdam Pharma Co. NV | -64.14M |
| argenx SE | -- |
| Mirum Pharmaceuticals, Inc. | -67.23M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 10.18M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.0923 |
| Enterprise Value | 114.03M |
| Gross Profit Margin (Quarterly) | 91.93% |
| Profit Margin (Quarterly) | -99.65% |
| Earnings Yield | -28.54% |
| Normalized Earnings Yield | -28.58 |